[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"darolutamide-daro-in-combination-with-androgen-deprivation-therapy-adt-and-docetaxel-doc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:darolutamide-daro-in-combination-with-androgen-deprivation-therapy-adt-and-docetaxel-doc":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100595346","evaluation-of-the-efficacy-of-darolutamide-triplet-therapy-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-100595346",false,"NCT07031258","Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer","Prospective Real-world Data Evaluation of Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC) in Patients With Metastatic Hormone-sensitive Prostate Cancer","Inclusion Criteria:\n\nVoluntarily signed informed consent form and able to understand and agree to comply with study requirements; Age ≥18； Male； Patients diagnosed with metastatic hormone-sensitive prostate cancer via CSCO guidelines, histopathology, etc.； Patients determined by treating physician to require darolutamide triplet therapy ECOG performance status score of 0-1 as evaluated by the Eastern Cooperative Oncology Group (ECOG) criteria； Life expectancy of over 1 year； Good compliance with regular serum PSA testing during treatment；\n\nExclusion Criteria:\n\nPresence of other malignancies within the past 2 years or currently; Severe cardiovascular\u002Fcerebrovascular disease within 6 months prior to study treatment initiation, including: severe\u002Funstable angina, myocardial infarction, congestive heart failure \\[NYHA Class III or worse\\], stroke, or arrhythmia requiring medication; Allergy to any study drug or excipient; Inability to swallow, chronic diarrhea, intestinal obstruction, or other factors affecting drug intake\u002Fabsorption; Underlying medical condition\u002Falcohol or drug abuse\u002Fdependence that may interfere with drug administration, result in adverse events, or complicate outcome interpretation; Participation in another therapeutic clinical study; Deemed unsuitable for the study by the investigator.","MALE","18 Years",{"count":19,"type":20},50,"ESTIMATED","1 Year","OBSERVATIONAL","The purpose of this study is to investigate the clinical efficacy and safety of darolutamide combined with androgen deprivation therapy (ADT) and different dose-intensity docetaxel chemotherapy in the treatment of patients with metastatic hormone-sensitive prostate cancer.",[25,26],"Metastatic Hormone-sensitive Prostate Cancer","Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)","NOT_YET_RECRUITING","2025-06-12",{"date":30,"type":31},"2025-06-22","ACTUAL",{"date":33,"type":20},"2025-06",{"date":35,"type":20},"2027-06",{"name":37,"class":38},"Nanfang Hospital, Southern Medical University","OTHER"]